Healthcare / Diagnostics & ResearchWarsaw
$10.44
-0.24 (-2.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-2.4M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$44M
P/E
69.6x
↑EV/EBITDA
12.4x
↑ROE
1.1%
↑Gross Margin
44.0%
↓Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-12.6%
FCF CAGR
—
FCF margin
-4.6%
FCF / Net income
-4.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $52.9M · net income $535000.0 · FCF $-2.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $52.9M | $52.9M | $46.8M | $143.9M | $79.1M |
| Net Income | $535000.00 | $535000.00 | $586000.00 | $28.9M | $10.2M |
| EBITDA | $4.6M | $4.6M | $3.3M | $38.4M | $14.6M |
| EPS | 0.13 | 0.13 | 0.14 | 6.48 | 2.29 |
| Gross Margin | 44.0% | 44.0% | 42.8% | 37.7% | 36.7% |
| Operating Margin | 2.1% | 2.1% | -0.5% | 24.1% | 16.6% |
| Net Margin | 1.0% | 1.0% | 1.3% | 20.1% | 13.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | 0.27 | 0.11 | 0.59 |
| Current Ratio | 1.41 | 1.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.4M | $-2.4M | $-16.5M | $27.2M | $-4.6M |
| Returns | |||||
| ROE | 1.1% | 1.1% | 1.2% | 55.1% | 35.1% |
| Valuation | |||||
| P/E | 69.60 | 69.60 | 115.43 | 4.58 | 16.15 |
| EV/EBITDA | 12.37 | 12.37 | 24.71 | 3.27 | 12.31 |
| P/B | 0.92 | 0.92 | 1.49 | 2.52 | 5.68 |
| Growth & Yield | |||||
| Revenue Growth | 13.0% | 13.0% | -67.5% | 81.9% | — |
| EPS Growth | -7.1% | -7.1% | -97.8% | 183.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
92.4%
EPS terminal req.
$0.93
Spread vs growth
-99.6%
5Y implied EPS CAGR
53.9%
EPS terminal req.
$1.12
Spread vs growth
-61.0%
10Y implied EPS CAGR
30.1%
EPS terminal req.
$1.81
Spread vs growth
-37.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.3%
Start / end P/E
104.3x → 82.8x
EPS bridge
0.14 → 0.13
Residual
+1.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.